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A novel COL4A5 mutation causes rapid progression to
end-stage renal disease in males, despite the absence of
clinical and biopsy findings associated with Alport syndrome.
Affected males have proteinuria, variable hematuria, and an
early progression to end-stage renal disease. Renal biopsy
findings include global and segmental glomerulosclerosis,
mesangial hypercellularity and basement membrane immune
complex deposition. Exon sequencing of the COL4A5 locus
identified a thymine to guanine transversion at nucleotide
665, resulting in a phenylalanine to cysteine missense
mutation at codon 222. The phenylalanine at position 222 is
absolutely conserved among vertebrates. This mutation was
confirmed in 4 affected males and 4 female obligate carriers,
but was absent in 6 asymptomatic male family members and
198 unrelated individuals. Immunostaining for a5(IV)
collagen in renal biopsies from affected males was normal.
This mutation, in a non-collagenous interruption associated
with severe renal disease, provides evidence for the
importance of this structural motif and suggests the range of
phenotypes associated with COL4A5 mutations is more
diverse than previously realized. Hence, COL4A5 mutation
analysis should be considered when glomerulonephritis
presents in an X-linked inheritance pattern, even with a
presentation distinct from Alport syndrome.
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A network formed by self-assembly of a3a4a5(IV) collagen in
the glomerular basement membrane (GBM) maintains the
structural integrity of the filtration barrier. This function is
compromised by certain mutations in the COL4A3, COL4A4, or
COL4A5 genes, which encode the a3-a5(IV) collagen chains,
causing hereditary nephropathies.1 Mutations in the COL4A3
or COL4A4 genes cause autosomal recessive or dominant
Alport syndrome.2 Mutations in the COL4A5 gene, located at
Xq22, present as X-linked Alport syndrome (XLAS; OMIM no.
301050), which is the most prevalent form of hereditary
nephritis.3 The clinical course of XLAS is heterogeneous based
on the type of GBM changes, the age of progression to end-stage
renal disease (ESRD), and the presence of extrarenal manifesta-
tions.4,5 Characteristic findings in males include microscopic
hematuria in 100%, gross hematuria in 60–70%, proteinuria in
90%, hearing loss in 90%, and ocular abnormalities in 35%.5,6
On renal biopsy, extensive thickening and splitting of the GBM
in the absence of immune complex (IC) deposition is strongly
suggestive of XLAS.6 Female heterozygotes for COL4A5
mutations are less symptomatic than males, but have micro-
scopic hematuria in 95% of cases.7
More than 400 mutations in the COL4A5 gene have been
described.8 Large case series of XLAS patients have led to the
classification of mutations and genotype–phenotype associa-
tions.4,5,9,10 Major alterations of COL4A5—including dele-
tions, frame-shift mutations, donor splice site mutations,
and nonsense mutations—result in the absence or severe
truncation of the COL4A5 protein, causing severe XLAS;
these patients are characterized by juvenile onset of ESRD
and extrarenal features, such as hearing loss and ocular
defects.5 In contrast, missense mutations of COL4A5 alter one
amino acid residue but produce an otherwise intact COL4A5
protein, generally causing a less severe clinical presentation,
with adult onset of ESRD and fewer extrarenal manifestations.5
The goal of this study was to identify the genetic alteration
responsible for juvenile-onset ESRD in multiple related males
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 13 May 2010; revised 29 June 2010; accepted 21 July 2010;
published online 29 September 2010
Correspondence: Andrew L. Schwaderer, Division of Nephrology,
Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, Ohio
43205, USA. E-mail: Andrew.Schwaderer@nationwidechildrens.org
120 Kidney International (2011) 79, 120–127
of a large pedigree. We report the identification of a novel
missense mutation in the COL4A5 gene strongly associated
with kidney disease in this cohort. This mutation occurs
within a non-collagenous interruption of the a5(IV) collagen
chain, providing the first direct evidence for the functional
importance of this structural motif.
RESULTS
Patients
A pedigree consisting of 117 individuals across 7 generations
identified 8 affected males with ESRD and 11 carrier or
obligate carrier females (Figure 1). No females were identified
with a history of chronic kidney disease. Medical records
were available from seven of the affected males; DNA samples
were obtained from five affected males, four carrier females
and six unaffected males. The absence of glomerular disease
in unaffected males was confirmed with a dipstick urinalysis
with no more than trace blood or protein.
Presentation and clinical course
The clinical presentation of affected males (Table 1) was
notable for proteinuria, hypertension, and renal dysfunction
with variable hematuria. The two males with no hematuria at
presentation did not develop persistent hematuria during
progression to ESRD. Two of the patients had documented
hypoalbuminemia and four patients had nephrotic range
proteinuria. Two affected males had normal audiograms at
presentation, and none reported hearing loss or hearing aid
requirements at the time of consent or had documentation of
hearing loss in the medical records. One patient had visual
changes, determined to be secondary to pseudotumor
cerebri. No patients had documented anterior lenticonus or
esophageal leiomyomatosis. One patient had linear immuno-
globulin G (IgG) deposits on a renal allograft biopsy. One of
the evaluated female carriers had trace hematuria, and two
out of three (67%) manifested 100mg/dl of proteinuria.
Renal biopsy findings
Records from nine renal biopsies performed on seven patients
were reviewed (Table 2). Tissue from five biopsies was available
for review. Light microscopy findings included global and
segmental sclerosis (Figure 2a) and mesangial expansion
(Figure 2b). No foam cells were identified. Immunofluores-
cence was consistently positive for IgM (granular) in the
GBM, with weak (1þ ) intensity. No biopsy was positive for
IgA. Electron microscopy revealed scattered electron dense
deposits in the GBM (Figure 3). Podocyte foot process
effacement was present in areas with and without basement
membrane dense deposits (Figure 3). Three of the NCH
biopsies had small subepithelial lucent areas suggestive for
resolved deposits. Only one patient had splitting of the GBM.
However, the splitting was confined to areas of dense deposits
or lucent areas, indicating that it was most likely a secondary
change. No patient had diffuse thinning of the GBM.
COL4A5 sequencing
Sequencing of the coding region for COL4A5 identified a
thymine to guanine (T4G) transversion at nucleotide 665
(T665G) in exon 12 of the index patient, resulting in a single
phenylalanine to cysteine (Phe-Cys) amino acid substitu-
tion at codon 222 (p.F222C). Exon 12 was subsequently
amplified by PCR from genomic DNA of additional family
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Figure 1 | Extended pedigree. Carriers are indicated by gray circles. Affected males are indicated by black squares. Individual 308
(square with vertical stripes) died of renal failure by history; however, records to determine the precise etiology were not available. The
index patient is indicated by an arrow.
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members and sequenced (Supplementary Figure S1 online).
We confirmed the presence of the mutation in another 4
affected males; in addition, one mutant allele was present in 4
carrier females and absent in 6 asymptomatic males (Table 3),
as well as 198 unrelated individuals. These findings suggest
that the p.F222C mutation is causative of the X-linked
glomerulopathy in this family.
Renal survival
All affected males developed ESRD. The age of 50% renal
survival was 16 years in males with the p.F222C mutation
compared with 28 years, 26 years, and 22 years in historical
controls with COL4A5 splice site mutations, missense muta-
tions, and large rearrangements, nonsense and deletion/
insertion mutations, respectively (Figure 4).9,10
Expression of collagen IV chains
Immunohistochemistry (IHC) was performed on available
diagnostic renal biopsy tissue from four affected males, as
well as positive and negative controls. Results were consistent,
with all four biopsies demonstrating positive (but slightly
lighter than positive control) staining for a1(IV) collagen and
a3(IV) collagen, and positive staining for a5(IV) collagen.
Representative results are presented in Figure 2c.
DISCUSSION
We report a series of related male patients whose presentation
and clinical course included proteinuria with variable
hematuria; mesangial hypercellularity with IC deposition
on renal biopsy; and rapid progression to ESRD. We
identified a novel T4G transversion at nucleotide 665 in
COL4A5, which segregated in affected males and female
carriers but was absent in unaffected males and 198 unrelated
individuals, indicating that it is likely causative. The amino
acid residue altered by this mutation, Phe-222, occurs within
one of the 22 breaks that interrupt the Gly–X–Y repeats
comprising the collagenous domain of the a5(IV) collagen
chain.4 The amino acid sequence of this interruption,
Table 1 | Clinical presentation and course
Patient How diagnosed
BP and
physical
examination
Initial serum
labs
Initial urine
laboratory
data Treatment
Age at diagnosis/
onset of ESRD
(year) Long term outcome
501 Data not available. Data not
available.
Data not
available.
Data not
available.
Data not
available.
Unknown/
17
Two renal transplants. Linear
fluorescence for IgG noted on
renal allograft biopsy. This
patient died at age 26 years.
516 Proteinuria was
identified during
the annual primary
care evaluation.
BP, 132/70.
No edema.
ANA, negative.
Cr, 0.4mg/dl.
C3, 130mg/dl.
2+ Protein.
Small blood.
20–30 rbcs/hpf.
Prednisone
and leukeran.
9/16 A renal transplant has been
functioning for the last 24 years.
529 Proteinuria was
identified during
the annual primary
care evaluation.
Data not
available.
Data not
available.
Data not
available.
Data not
available.
13/16 The patient has had three renal
transplants.
528 Proteinuria was
identified during
the annual primary
care evaluation.
BP, 120/90.
No edema.
ANA, negative.
Cr, 1.1mg/dl.
C3, 86mg/dl.
4+ Protein.
5–10 rbcs/hpf.
Data not
available.
9/13 A renal transplant has been
functioning for the last 27 years.
620 A renal evaluation
was performed
secondary to
renal disease
in his brother.
BP, 170/110.
Pretibial and
periorbital
edema.
Albumin,
2.5 g/dl.
Cr, 2.2mg/dl.
C3, 95mg/dl.
C4, 14mg/dl.
4+ Protein.
Trace blood.
Ace
inhibition.
17/22 A renal transplant has been
functioning for the last 19 years.
621 The patient was
noted to be
hypertensive during
an evaluation for
headaches.
BP, 150/100.
No edema.
Albumin,
2.2 g/dl.
ANA, negative.
Cr, 4.3mg/dl.
C3, 141mg/dl.
C4, 28mg/dl.
4+ Protein.
No blood.
5.4mg/kg/hr
of protein.
Ace
inhibition
and imuran.
13/14 A renal transplant has been
functioning for the last 21 years.
609 The patient
was evaluated
in the emergency
department with
nausea, vomiting
and fatigue.
BP, 220/150.
No edema.
ANA, negative.
Cr, 11.4mg/dl.
C3, 130mg/dl.
C4, 31mg/dl.
4+ Protein.
o1 rbc/hpf.
Protein: Cr,
15.2mg/mg.
Renal
replacement
therapy.
10/10 The patient has been
transplanted within the
last year.
Abbreviations: Ace, angiotensin-converting enzyme; ANA, anti-nuclear antibody; BP, blood pressure; Cr, creatinine; hpf, high-power field; IgG, immunoglobulin G; rbc, red
blood corpuscle.
The clinical presentation and course of seven related male patients are summarized. Numbers designate the location of each patient in the extended pedigree (Figure 1).
Serum creatinine in mg/dl may be converted to mmol/l by multiplying by 88.4. Blood pressures are listed as mmHg.
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GLNFQG, has been phylogenetically conserved from fish to
mammals suggesting an important structural and functional
role for this interruption (Figure 5).
Breaks in Gly–X–Y repeats introduce bends in the collagen
triple helix, create flexible sites, and may form binding
sites.11,12 G4G interrupts (Gly–X1–X2–X3–X4–Gly) and G1G
(Gly–X1–Gly) interrupts are the most common in all collagen
IV chains.13 Peptide studies show that G4G interrupts have
an ordered structure, forming a pseudo-triple helix, in which
hydrophobic interactions among residues at the X3 posi-
tion—like Phe-222—replace glycine packing in the triple
helix.14,15 Substitution of Phe-222 is predicted to disrupt
these hydrophobic interactions, altering the normal structure
of this G4G interruption. Development of severe kidney
disease in patients with the p.F222C mutation highlights the
functional importance of Phe-222. Notably, this is the first
collagen IV missense mutation causing severe kidney disease
that occurs within a Gly–X–Y interruption.
Although COL4A5 mutations typically cause XLAS, the
affected males in this study have clinical and pathological
features inconsistent with the classic presentation of XLAS.
Microscopic hematuria occurred in only three out of five
(60%) of the affected males and one out of three (33%) of the
carrier females in our series, compared with 100% of males
and 95% of females for XLAS.5,6 As the initial urinalysis in
affected males without hematuria was performed late in the
clinical course, it remains possible that hematuria is more
prominent in an earlier phase of the disease. Male patients
without hematuria concurrently had nephrotic range pro-
teinuria and elevated serum creatinine. The median renal
survival age was 15 years, compared with 25 years for XLAS.5
Despite the severity of the nephritis, there were no
documented extrarenal complications typically associated
with severe XLAS. However, such extrarenal manifestations
cannot be conclusively ruled out without formal audiologic
and ophthalmologic evaluation. Mesangial hypercellularity
and segmental sclerosis may be identified on renal biopsies of
XLAS patients, but are accompanied by more characteristic
findings.16 Although the basement membranes were thick-
ened, the absence of alternate thickening and thinning of the
GBM, known as ‘basket weaving’ and splitting of the GBM
(with the exception of one limited area in a single case that
was suggestive of a secondary change) is unusual for XLAS.16
Basement membrane electron dense deposits and positive
immunofluorescence are generally thought to be inconsistent
with XLAS, though exceptions have been reported in AS
Table 2 | Renal biopsy findings
Patient 501 516 516 528 529a 529 620 621 609
Age at biopsy (years) Unknown 9 14 10 13 16 17 13 9
Biopsy reviewed at NCH + + + + +
Light microscopy
Mesangial expansion + + + + + + +
FSGS + + + + + +
Global sclerosis (affected/total) +
1/15
+
2/8
+ +
All
+
9/21
+
3/6
+
16/19
Interstitial fibrosis + + +
Inflammation + +
Immunofluorescence
IgA
IgM +
gbm
+
gbm
+ +
gbm
mes
+
gbm
mes
+
gbm
IgG +
gbm
+
C3 +
gbm
+
mes
+ +
gbm
mes
+
gbm
Electron microscopy
Electron dense deposits +
s-ep
i-me
s-en
+
s-en
i-me
mes
+ +
s-en
s-ep
mes
i-me
+
s-en
s-ep
mes
GBM splitting +b +b
Lucent areas +
s-ep
+ +
s-ep
+
s-ep
Abbreviations: FSGS, focal segmental glomerulosclerosis; gbm, glomerular basement membrane; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M;
i-me, intramembranous; mes, mesangium; NCH, Nationwide Children’s Hospital; s-en, subendothelial; s-ep, subepithelial.
Shaded cells indicate when data was not available.
The renal biopsy findings of seven related male patients are summarized. In certain cases, serial biopsies were available. Patients are designated according to their location in
the family pedigree (Figure 1). The presence of a finding is indicated by a ‘+’ symbol in the appropriate box.
aSpecific details of light microscopy not available, but findings reported as ‘normal’.
bThe splitting was confined to areas of deposits or lucent areas.
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patients.17,18 In addition, IC deposition has been reported in
Alport syndrome patients with a coexisting glomerulopathy,
that is, dual glomerulopathy.19,20 The mechanism of IC
deposition in patients with COL4A5 mutations is not known.
We were unable to detect the presence of circulating anti-
GBM antibodies in serum from the index patient by indirect
immunofluorescence (D-BB, WL, data not shown); however,
material from additional affected individuals was unavailable,
and it remains conceivable that serum factors (such as
autoantibodies) could account for the glomerular deposition
of ICs. Alternatively, structural changes in the collagen IV
network of the GBM may lead to IC trapping independent of
antigen recognition, which in turn contributes to glomerular
damage. The presence of IC raises the question of whether
antibody trapping leads to complement activation and the
potential role of complement in glomerular damage in
Affected Control
α1
*
α3
α5
Figure 2 | Light microscopy and immunohistochemistry
findings in the renal biopsy. (a) Jones silver staining
demonstrated segmental sclerosis (arrowheads). No splitting,
spikes or lucencies were evident in the glomerular basement
membrane (GBM) (arrows). (b) Periodic acid-Schiff staining
demonstrates mesangioproliferative glomerulonephritis with
increased mesangial matrix and mesangial cellularity
(arrowheads). Magnification  400. (c) Staining for a1(IV), a3(IV),
and a5(IV) collagen was found in the GBM (arrowheads), although
a3(IV) staining was slightly diminished in affecteds. Positive
staining was present in the tubular basement membranes
(arrows); this staining was diffuse for a1(IV) collagen and focal for
a3 (not shown) and a5 chains of type IV collagen. a1(IV) and
a5(IV) collagen was also expressed in the basement membranes
of Bowman’s capsule (asterisks).
Figure 3 | Electron microscopy findings in the renal biopsy.
Electron microscopy results are presented with electron dense
immune complex (arrows) deposition. Effacement of the
podocyte foot processes is present (arrowheads).
Table 3 | COL4A5 genotyping and screening UA results
Subject Phenotype Blood Protein Genotype
409 UN Negative Trace
413 UN Negative Trace WT
502 UN Negative Trace WT
541 UN Negative Trace
518 UN Negative Trace WT
520 UN Negative Trace WT
525 UN Negative Trace WT
619 UN WT
408 C Negative 2+
410 C Trace 2+ WT/T665G
506 C Negative Trace WT/T665G
523 C WT/T665G
708 C WT/T665G
516 A T665G
528 A T665G
620 A T665G
621 A T665G
609 A T665G
Abbreviations: A, affected; C, carrier; UN, unaffected; WT, wild type.
Subjects are designated according to their location in the extended pedigree
(Figure 1) and grouped according to their clinical phenotype, as UN, C, or A. When
available, the results of dipstick urinalysis for blood and protein are listed (negative).
Results of COL4A5 nucleotide 665 genotyping are listed as WT or the T665G
transversion. Shaded cells indicate when data was not available.
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affected patients. There was no evidence of hypocomple-
mentemia in all examined individuals at presentation
(Table 1), arguing against complement activation. Immuno-
fluorescence demonstrated positive C3 in five out of six
biopsies examined, with GBM localization in three out of five
cases (Table 2). The presence of C3 deposition in the GBM
has been reported in XLAS, particularly in segmental lesions
with progression of disease.21 Whether this represents non-
specific trapping of C3 along with antibodies such as IgG and
IgM or complement activation is unclear at this time.
The positive staining for a5(IV) and a3(IV) collagen in
the renal biopsies of the affected patients indicates that the
p.F222C mutation does not interfere with the assembly of
a3a4a5(IV) collagen. This is not surprising, because the
specific assembly of a3a4a5(IV) molecules and networks is
driven by molecular recognition sites within the non-
collagenous (NC1) domains at the carboxyl end of each
collagen IV chain.22,23 The most frequently detected missense
mutations map to conserved glycine residues within the
Gly–X–Y repeats comprising the collagenous domain of
a5(IV) collagen.5,24 Mutations of these glycine residues
introduce an abnormal break in the collagen triple helix,
altering the structure and reducing the stability of
a3a4a5(IV) molecules. As a result, the affected patients
develop comparatively milder forms of XLAS.5 More severe
forms of XLAS, with juvenile onset of ESRD, are caused by
COL4A5 mutations such as large deletions, nonsense
mutations, or splice site donor mutations that yield a
truncated a5(IV) chain lacking the NC1 domain.5 Because
these mutations prevent the assembly of a3a4a5(IV)
heterotrimers, they cause the absence of a3, a4 and a5(IV)
collagen from the GBM, resulting in a more severe
phenotype.25 In our series of patients, severe kidney disease
is not due to the impaired deposition of a3a4a5(IV) collagen
in the GBM, but may reflect a specific functional impairment
of this network caused by the p.F222C mutation.
Although the precise mechanism whereby the p.F222C
mutation results in kidney disease remains to be determined,
some contributing factors may be inferred. As discussed, the
pseudo-triple helical structure of G4G interruptions is
stabilized by interactions among hydrophobic residues at
the third position, such as Phe-222. Although cysteine is
hydrophobic, it is not a conservative substitution for
phenylalanine because of its smaller size and propensity to
Minor non-collagenous domain Collagenous domain NC1 domain
7S
Majority
Human COL4A5.pro
Macaque COL4A5.pro
Dog COL4A5.pro
Cow COL4A5.pro
Mouse COL4A5.pro
Rat COL4A5.pro
Chicken COL4A5.pro
Xenopus COL4A5.pro
Stickleback COL4A5.pro
Takifugu COL4A5.pro
Tetraodon COL4A5.pro
Zebrafish COL4A5.pro
Figure 5 |Phylogenetic conservation of the Phe-222 residue. Type 4 collagens consist of a minor non-collagenous domain, a minor
collagenous (7S) domain, a major collagenous domain containing 15–20 noncollagenous interruptions and a carboxyl terminal non-
collagenous (NC1) domain.32,33 The area of the non-collagenous interruption affected by the p.F222C mutation is represented by the
dashed lines. The alignment of the predicted COL4A5 protein sequences from 12 species reveals the complete conservation of the Phe-222
residue in vertebrates.
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Figure 4 |Renal survival curves. Patients with the p.F222C
mutation (n¼ 7) progressed to ESRD at a more rapid rate than
historical controls with splice site mutations (n¼ 13), missense
mutations (n¼ 21), and large rearrangements, nonsense and
deletion/insertion mutations (n¼ 23) reported by Martin et al.30
and Gross et al.9 Differences between patients with the p.F222C
mutation and patients with other types of mutations were highly
significant (Po0.001).
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form disulfide bonds. The collagenous triple helix of a3a4a5(IV)
molecules is characterized by numerous intra- and intermolecular
disulfide bridges.26 The collagenous domains of a3(IV) and
a4(IV) contain 7 and 15 cysteine residues, respectively,
whereas that of a5(IV) (residues 42–1456) contains only
3 cysteine residues at positions 451, 481, and 484. Therefore,
introduction of a new cysteine at position 222 in the a5(IV)
chain can have a detrimental effect on the structure and
function of the a3a4a5(IV) collagen network by interfering
with the formation of the normal disulfide bonds and/or by
introducing a new disulfide bridge at an undesirable position.
Cysteine substitutions in other collagenopathies appear to
dramatically alter the phenotype. Defects of COL1A1 or
COL1A2 typically involve substitution of a glycine in the
Gly–X–Y repeat of the triple helix domain, resulting in osteo-
genesis imperfecta.27 Interestingly, when cysteine is substituted
for arginine in the triple repeat, the phenotype changes to that
of Ehlers–Danlos with a high propensity for arterial rupture
and minimal bone involvement.28 Functional studies indicate
the cysteine causes abnormal formation of disulfide bridges,
which can result in either premature degradation of the
protein or delayed secretion and formation of abnormal
collagen fibrils in the extracellular matrix (depending on the
location of the mutation). We speculate a similar phenomenon
may be occurring with this COL4A5 mutation, with secretion
of an intact but abnormal protein.
Because of random X chromosome inactivation, females
carriers with XLAS have variable expression of the mutant
a5(IV) collagen chain—even within a given glomerulus—and as
many as 25% develop severe renal disease.29 Of the five carrier
females enrolled in our study, all denied a history of abnormal
renal function upon interview, and renal function tests were not
available. Yet two out of the three (67%) carrier females evaluated
by urine dipstick did manifest 2þ proteinuria, suggestive of
GBM abnormalities. Whether GBM abnormalities do occur and
result in subclinical disease could not be further assessed because
of the absence of kidney biopsy tissue from carrier females.
In summary, we have described a set of patients with
X-linked glomerulopathy without characteristic findings of
XLAS by clinical history or renal biopsy findings who
progressed to ESRD at an early age. To our knowledge, this is
the first report to associate IC deposition with a specific
mutation in the COL4A5 gene. Our findings emphasize that
the detection of IC deposition should not exclude the
diagnosis of XLAS, nor should it automatically implicate the
p.F222C mutation described in this study. In addition, this is
the first COL4A5 mutation associated with rapid progression
to ESRD, in patients otherwise lacking the characteristic
clinical and biopsy findings associated with XLAS. Finally,
this is the first COL4A5 missense mutation that occurs within
a non-collagenous interrupt of a5(IV) collagen. Testing for
COL4A5 mutations should be a consideration when glomer-
ulopathy presents with an X-linked inheritance pattern,
regardless of the consistency of the presentation with XLAS.
Future studies should identify the structural and functional
differences between mutant and wild-type COL4A5 protein
and determine if the p.F222C mutation is also present in
unrelated patients with similar biopsy findings.
METHODS
Patient selection
This study was approved by the Nationwide Children’s Hospital
Institutional Review Board. Participants were enrolled with informed
consent. A pedigree was constructed based on interviews and historical
records. Dipstick urinalysis was performed by presumed unaffected
male as well as female family members. Controls comprised race-
matched individuals of North European ancestry from Centre de’ Etude
du Polymorphisme Humain (Paris, France) families (120 individuals)
obtained from the Coriell Cell Repository (Camden, NJ), and from
central Ohio (78 individuals).
DNA isolation and COL4A5 sequencing
DNA isolated from peripheral blood of the index patient (no. 609)
was submitted for exon sequencing of COL4A5 (Athena Diagnostics,
Worcester, MA). For sequencing of COL4A5 exon 12, DNA was
isolated from saliva (Oragene, Kanata, Ontario, Canada). PCR Primers
flanking exon 12 of COL4A5 were: 50-TATCTTTTATTTGGTGTG
GA-30 and 50-TCAAGAAGCAAGAGAAAGAA-30. Conditions were:
10min at 94 1C; then 36 cycles of 94 1C for 30 s, 59.3 1C for 30 s,
72 1C for 45 s; then 72 1C for 10min, then 4 1C. PCR reactions were
purified and sequenced bidirectionally.
Probability of ESRD curve analysis
Graphs for the age of ESRD in the affected males with the p.F222C
mutation and historical controls9,30 were generated with GraphPad
Prism v5.0b (GraphPad Software, La Jolla, CA) by the Kaplan–Meier
method. Differences between curves were analyzed for significance
with the Log-rank (Mantel–Cox) Test.31
IHC analyses
As the frozen sections were not available, expression of collagen IV
chains was analyzed by IHC using 3-mm thick sections of formalin-
fixed, paraffin-embedded renal needle biopsies. IHC was automated
on the BondMax IHC system (Leica Microsystems, Bannockburn, IL)
For antigen retrieval, sections were treated with proteinase K for 10min
at 37 1C. Mab-1 and Mab-5 (Alpco Diagnostics, Salem, NH) were used
for staining a1(IV) and a5(IV) collagen, respectively. Mab-5D6,
used for detection of a3(IV) collagen, is a murine IgG2a monoclonal
antibody raised against recombinant human a3NC1 monomers
(Molecular Recognition Shared Facility, Vanderbilt University). The
specificity of mAb 5D6 was verified by indirect ELISA using recom-
binant NC1 monomers and by immunofluorescence staining of
normal human kidney (D-BB, unpublished observations). Staining
with mAb 5D6 or Mab-5 was performed after treatment with acid
urea (Alpco Diagnostics). Positive-control sections were obtained
from a normal autopsy kidney. Negative controls were obtained by
substituting the primary antibody with a Universal Negative Control
Serum (cat no. NC49BL, Biocare Medical, Concord, CA).
Evaluation of phylogenetic sequence conservation
Protein sequence alignments to evaluate phylogenetic sequence
conservation were performed with MegAlign (DNASTAR, Madison,
WI), using the Clustal W method.
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